These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9451363)

  • 21. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pramipexole in the treatment of advanced Parkinson's disease.
    Möller JC; Oertel WH
    Eur J Neurol; 2000 May; 7 Suppl 1():21-5. PubMed ID: 11054155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
    Baker WL; Silver D; White CM; Kluger J; Aberle J; Patel AA; Coleman CI
    Parkinsonism Relat Disord; 2009 May; 15(4):287-94. PubMed ID: 18774743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine agonists in early therapy for Parkinson disease: promise and problems.
    Tanner CM
    JAMA; 2000 Oct; 284(15):1971-3. PubMed ID: 11035895
    [No Abstract]   [Full Text] [Related]  

  • 28. DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S98-102. PubMed ID: 12211149
    [No Abstract]   [Full Text] [Related]  

  • 29. DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S90-2. PubMed ID: 12211147
    [No Abstract]   [Full Text] [Related]  

  • 30. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Montgomery EB
    Neurology; 2004 Jan; 62(2):343; author reply 343-5. PubMed ID: 14745094
    [No Abstract]   [Full Text] [Related]  

  • 31. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine agonists in Parkinson's disease.
    Yamamoto M; Schapira AH
    Expert Rev Neurother; 2008 Apr; 8(4):671-7. PubMed ID: 18416667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pramipexole (Mirapex) for restless legs syndrome.
    Med Lett Drugs Ther; 2007 Mar; 49(1257):26-8. PubMed ID: 17375031
    [No Abstract]   [Full Text] [Related]  

  • 34. DA agonists -- ergot derivatives: dihydroergocryptine (DHEC): management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S72-3. PubMed ID: 12211143
    [No Abstract]   [Full Text] [Related]  

  • 35. Dopamine agonists and neuroprotection in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2002 Nov; 9 Suppl 3():7-14. PubMed ID: 12464116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study.
    Sziklai I; Szilvássy J; Szilvássy Z
    Laryngoscope; 2011 Apr; 121(4):888-93. PubMed ID: 21433025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New dopamine agonists on the horizon.
    Heins JR
    S D J Med; 1997 Jul; 50(7):239-40. PubMed ID: 9240032
    [No Abstract]   [Full Text] [Related]  

  • 38. Alopecia induced by dopamine agonists.
    Tabamo RE; Di Rocco A
    Neurology; 2002 Mar; 58(5):829-30. PubMed ID: 11889256
    [No Abstract]   [Full Text] [Related]  

  • 39. D-3 receptor agonists: combined action neurologic and neuropsychiatric agents.
    Cummings JL
    J Neurol Sci; 1999 Feb; 163(1):2-3. PubMed ID: 10223401
    [No Abstract]   [Full Text] [Related]  

  • 40. Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone?
    Fernandez HH; Merello M
    Lancet Neurol; 2010 Jun; 9(6):556-7. PubMed ID: 20452824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.